Can-Fite BioPharma (CANF) files H1 2025 results and pipeline update

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. filed a Form 6-K as a foreign private issuer to provide investors with its operating and financial review and unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025. The company also issued a press release on that date summarizing its financial results for the period and giving updates on its drug development programs. The 6-K specifies that the financial review, interim financial statements, and portions of the press release are incorporated by reference into several existing Form S-8 and Form F-3 registration statements, allowing those registration statements to use the newly furnished information.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of August 2025

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

This Report on Form 6-K, Exhibit 99.1, Exhibit 99.2 and the text under the heading “Financial Results” and “Forward-Looking Statements” in the press release in Exhibit 99.3 are hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384 and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000 and 333-281872), to be a part there of from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On August 28, 2025, Can-Fite BioPharma Ltd. (the “Company”) issued a press release announcing financial results for the six months ended June 30, 2025 and updates on its drug development programs. In addition, on the same day, the Company issued unaudited interim condensed consolidated financial statements as of June 30, 2025. Attached hereto and incorporated by reference herein are the following exhibits:

99.1		Operating and Financial Review and Prospects as of June 30, 2025
99.2		Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2025
99.3		Press Release dated August 28, 2025
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

1

Exhibit Index

Exhibit No.		Description
99.1		Operating and Financial Review and Prospects as of June 30, 2025
99.2		Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2025
99.3		Press Release dated August 28, 2025
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 28, 2025	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

3

FAQ

What period does Can-Fite BioPharma Ltd. (CANF) cover in this Form 6-K?

The Form 6-K covers Can-Fite BioPharma Ltd.’s operating and financial review and unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025.

What key documents are included as exhibits in Can-Fite BioPharma’s August 2025 Form 6-K?

The exhibits include an Operating and Financial Review and Prospects as of June 30, 2025 (Exhibit 99.1), Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2025 (Exhibit 99.2), and a press release dated August 28, 2025 (Exhibit 99.3), along with related Inline XBRL files and the cover page interactive data file.

What does the August 28, 2025 press release from Can-Fite BioPharma (CANF) describe?

The press release dated August 28, 2025 announces financial results for the six months ended June 30, 2025 and provides updates on Can-Fite BioPharma’s drug development programs.

How is this Can-Fite BioPharma Form 6-K used in connection with existing registration statements?

The Form 6-K states that Exhibit 99.1, Exhibit 99.2, and the sections titled “Financial Results” and “Forward-Looking Statements” in the press release in Exhibit 99.3 are incorporated by reference into the company’s registration statements on Form S-8 and Form F-3 listed by file number.

What type of SEC annual report framework does Can-Fite BioPharma (CANF) follow?

The Form 6-K indicates that Can-Fite BioPharma Ltd. files its annual reports under cover of Form 20-F, consistent with its status as a foreign private issuer.

Who signed the August 2025 Form 6-K for Can-Fite BioPharma Ltd.?

The report was signed on behalf of Can-Fite BioPharma Ltd. by Motti Farbstein, who is identified as Chief Executive Officer and Chief Financial Officer.